Enabling Data Integrity from Drug Discovery through Manufacturing
White Paper Sep 19, 2018
When discussing the success of a drug therapy, a common topic amongst biopharmaceutical companies is data quality and data integrity; what the challenges are and what the key elements are to ensuring that the latest discovery is patentable, does not result in re-conducting critical research or development studies, is accepted by the regulators, or does not result in a recall of a batch of product.
A common challenge expressed amongst the industry is how to implement processes that promote and ensure that regulatory guidance’s are being followed and that their data is of the highest integrity.
High data quality and integrity is critical to ensure patient safety and drug efficacy from research and development through to manufacturing.
Related White Papers
This study from Malvern Panalytical looks at optimal conditions for extruding liposomes as well as their stability under different conditions, highlighting the limit of detection for fluorescently labeled liposomes.
READ MOREThis document describes how Malvern Panalytical systems support system owners, meeting the requirements of the 21 CFR Part 11 regulations issued by the United States’ FDA.
READ MOREDownload this white paper to learn all about hybridoma-based antibody development, including their key benefits and misconceptions.
READ MORELike what you just read? You can find similar content on the communities below.
BiopharmaTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
